Onconetix Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Onconetix has an operating margin of -2238.0%, meaning the company retains $-2238 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -61634.5% the prior year.
Onconetix's revenue surged 4217.3% year-over-year to $2.5M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Onconetix has a moderate D/E ratio of 2.17. This balance of debt and equity financing earns a leverage score of 31/100.
Onconetix's current ratio of 0.05 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.
While Onconetix generated -$10.5M in operating cash flow, capex of $28K consumed most of it, leaving -$10.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Onconetix passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Onconetix generates $0.18 in operating cash flow (-$10.5M OCF vs -$58.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Onconetix earns $-64.7 in operating income for every $1 of interest expense (-$56.5M vs $873K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Onconetix (ONCO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Onconetix generated $2.5M in revenue in fiscal year 2024. This represents an increase of 4217.3% from the prior year.
Onconetix's EBITDA was -$55.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 54.9% from the prior year.
Onconetix generated -$10.5M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 22.5% from the prior year.
Onconetix reported -$58.7M in net income in fiscal year 2024. This represents a decrease of 56.9% from the prior year.
Onconetix earned $-21.45 per diluted share (EPS) in fiscal year 2024. This represents an increase of 75.5% from the prior year.
Onconetix held $647K in cash against $0 in long-term debt as of fiscal year 2024.
Onconetix had 8M shares outstanding in fiscal year 2024. This represents a decrease of 55.5% from the prior year.
Onconetix's gross margin was 41.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 1969.7 percentage points from the prior year.
Onconetix's operating margin was -2238.0% in fiscal year 2024, reflecting core business profitability. This is up 59396.5 percentage points from the prior year.
Onconetix's net profit margin was -2325.2% in fiscal year 2024, showing the share of revenue converted to profit. This is up 61661.3 percentage points from the prior year.
Onconetix invested $154K in research and development in fiscal year 2024. This represents a decrease of 92.1% from the prior year.
Onconetix invested $28K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 762.8% from the prior year.
ONCO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $304K+185.1% | $106K+4.8% | $102K-90.0% | $1.0M+43.6% | $705K+76.2% | $400K | N/A | N/A |
| Cost of Revenue | $35K-3.4% | $36K-35.5% | $56K+7.3% | $52K-91.4% | $604K+18.1% | $511K | N/A | N/A |
| Gross Profit | $269K+281.4% | $71K+53.8% | $46K-93.1% | $660K+555.3% | $101K-46.7% | $189K | N/A | N/A |
| R&D Expenses | N/A | N/A | $24K-77.6% | $109K | N/A | $49K | N/A | $219K |
| SG&A Expenses | $2.3M+53.7% | $1.5M-9.0% | $1.7M-36.4% | $2.6M+18.5% | $2.2M-40.6% | $3.7M | N/A | $4.3M |
| Operating Income | -$2.1M-6.9% | -$1.9M+84.6% | -$12.6M+56.9% | -$29.1M-114.1% | -$13.6M-22.9% | -$11.1M | N/A | -$4.5M |
| Interest Expense | $300K+50.0% | $200K0.0% | $200K+22.0% | $164K+5.0% | $156K-61.0% | $400K | N/A | $269K |
| Income Tax | N/A | N/A | N/A | -$918K-1908.2% | $51K+141.8% | -$122K | N/A | N/A |
| Net Income | -$8.8M-270.2% | -$2.4M+72.2% | -$8.5M+71.0% | -$29.4M-105.8% | -$14.3M-28.7% | -$11.1M | N/A | -$5.3M |
| EPS (Diluted) | $-6.25 | $-4.76-798.1% | $-0.53-100.0% | $2439.30+211.3% | $-2191.59-10814.3% | $-20.08 | N/A | $-12.21 |
ONCO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $19.7M+2.9% | $19.1M+1.8% | $18.8M-33.4% | $28.2M-52.6% | $59.5M-20.7% | $75.0M-14.3% | $87.5M+213.9% | $27.9M |
| Current Assets | $1.3M+39.9% | $931K-61.6% | $2.4M+154.7% | $950K-53.3% | $2.0M-67.7% | $6.3M+7.8% | $5.8M-38.8% | $9.5M |
| Cash & Equivalents | $837K+195.1% | $284K-82.0% | $1.6M+144.0% | $647K-30.5% | $931K-79.2% | $4.5M-2.0% | $4.6M-40.5% | $7.7M |
| Inventory | $152K-1.0% | $153K-1.7% | $156K+142.9% | $64K-60.0% | $160K-59.6% | $396K+8.9% | $364K-74.3% | $1.4M |
| Accounts Receivable | $3K-79.0% | $12K-25.4% | $16K-36.6% | $26K-85.0% | $171K-32.2% | $253K+68.8% | $150K | N/A |
| Goodwill | $18.2M+0.3% | $18.1M+11.8% | $16.2M-40.1% | $27.0M-25.9% | $36.5M-21.9% | $46.7M-16.0% | $55.7M | N/A |
| Total Liabilities | $16.3M+27.7% | $12.8M-10.5% | $14.3M-23.2% | $18.6M-80.5% | $95.3M-1.3% | $96.6M+3.7% | $93.1M+427.7% | $17.6M |
| Current Liabilities | $16.3M+28.4% | $12.7M-9.6% | $14.0M-23.2% | $18.3M-11.2% | $20.6M-3.9% | $21.4M+24.7% | $17.2M-2.6% | $17.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3.4M-42.9% | $5.9M+48.0% | $4.0M-53.3% | $8.5M+123.9% | -$35.8M-66.3% | -$21.5M-284.4% | -$5.6M-154.7% | $10.2M |
| Retained Earnings | -$136.9M-6.9% | -$128.1M-2.2% | -$125.4M-8.4% | -$115.7M-40.7% | -$82.2M-21.1% | -$67.9M-19.6% | -$56.8M-64.9% | -$34.4M |
ONCO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M-125.3% | -$1.4M+29.5% | -$2.0M-117.9% | -$918K+71.3% | -$3.2M+38.8% | -$5.2M-21.3% | -$4.3M-41.8% | -$3.0M |
| Capital Expenditures | N/A | N/A | N/A | $4K-78.1% | $18K+286.8% | $5K | $0 | $0 |
| Free Cash Flow | N/A | N/A | N/A | -$922K+71.4% | -$3.2M+38.6% | -$5.2M-21.4% | -$4.3M-41.8% | -$3.0M |
| Investing Cash Flow | N/A | N/A | N/A | -$4K+78.1% | -$18K-286.8% | -$5K-100.4% | $1.2M+602.6% | $173K |
| Financing Cash Flow | $4.3M+476.3% | $745K-74.1% | $2.9M+120.3% | $1.3M+479.4% | -$343K-106.6% | $5.2M | $0-100.0% | $1.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $26K |
ONCO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.5%+22.3pp | 66.2%+21.1pp | 45.1%-20.1pp | 65.2%+50.9pp | 14.3%-33.0pp | 47.3% | N/A | N/A |
| Operating Margin | -681.4%+1136.0pp | -1817.4%+10551.8pp | -12369.2%-9490.3pp | -2878.9%-947.2pp | -1931.6%+838.9pp | -2770.5% | N/A | N/A |
| Net Margin | -2892.7%-664.9pp | -2227.8%+6181.1pp | -8408.8%-5501.1pp | -2907.8%-878.0pp | -2029.8%+749.9pp | -2779.6% | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -44.6%-32.2pp | -12.4%+33.1pp | -45.5%+58.9pp | -104.5%-80.4pp | -24.1%-9.2pp | -14.8% | N/A | -19.2% |
| Current Ratio | 0.080.0 | 0.07-0.1 | 0.17+0.1 | 0.05-0.0 | 0.10-0.2 | 0.29-0.0 | 0.34-0.2 | 0.54 |
| Debt-to-Equity | 4.83+2.7 | 2.16-1.4 | 3.57+1.4 | 2.17+4.8 | -2.66+1.8 | -4.48+12.1 | -16.62-18.3 | 1.72 |
| FCF Margin | N/A | N/A | N/A | -91.0%+365.4pp | -456.4%+852.7pp | -1309.2% | N/A | N/A |
Note: The current ratio is below 1.0 (0.05), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Onconetix's annual revenue?
Onconetix (ONCO) reported $2.5M in total revenue for fiscal year 2024. This represents a 4217.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Onconetix's revenue growing?
Onconetix (ONCO) revenue grew by 4217.3% year-over-year, from $58K to $2.5M in fiscal year 2024.
Is Onconetix profitable?
No, Onconetix (ONCO) reported a net income of -$58.7M in fiscal year 2024, with a net profit margin of -2325.2%.
What is Onconetix's earnings per share (EPS)?
Onconetix (ONCO) reported diluted earnings per share of $-21.45 for fiscal year 2024. This represents a 75.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Onconetix's EBITDA?
Onconetix (ONCO) had EBITDA of -$55.8M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Onconetix's gross margin?
Onconetix (ONCO) had a gross margin of 41.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Onconetix's operating margin?
Onconetix (ONCO) had an operating margin of -2238.0% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Onconetix's net profit margin?
Onconetix (ONCO) had a net profit margin of -2325.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Onconetix's free cash flow?
Onconetix (ONCO) generated -$10.5M in free cash flow during fiscal year 2024. This represents a 22.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Onconetix's operating cash flow?
Onconetix (ONCO) generated -$10.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Onconetix's total assets?
Onconetix (ONCO) had $28.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Onconetix's capital expenditures?
Onconetix (ONCO) invested $28K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Onconetix spend on research and development?
Onconetix (ONCO) invested $154K in research and development during fiscal year 2024.
How many shares does Onconetix have outstanding?
Onconetix (ONCO) had 8M shares outstanding as of fiscal year 2024.
What is Onconetix's current ratio?
Onconetix (ONCO) had a current ratio of 0.05 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Onconetix's debt-to-equity ratio?
Onconetix (ONCO) had a debt-to-equity ratio of 2.17 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Onconetix's return on assets (ROA)?
Onconetix (ONCO) had a return on assets of -208.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Onconetix's cash runway?
Based on fiscal year 2024 data, Onconetix (ONCO) had $647K in cash against an annual operating cash burn of $10.5M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Onconetix's Piotroski F-Score?
Onconetix (ONCO) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Onconetix's earnings high quality?
Onconetix (ONCO) has an earnings quality ratio of 0.18x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Onconetix cover its interest payments?
Onconetix (ONCO) has an interest coverage ratio of -64.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Onconetix?
Onconetix (ONCO) scores 26 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.